I-Vonoprazan Fumarate (TAK-438) CAS 1260141-27-2 881681-01-2 API Umgangatho ophezulu
Ukubonelela ngeVonoprazan Fumarate kunye neNxulumano ePhakathi
5-(2-Fluorophenyl)pyrrole-3-Carboxaldehyde CAS 881674-56-2
I-Pyridine-3-Sulfonyl Chloride CAS 16133-25-8
I-Vonoprazan Fumarate (TAK-438) CAS 1260141-27-2 881681-01-2
| Igama leMchiza | Vonoprazan Fumarate |
| Izithethantonye | I-TAK-438 |
| Inombolo yeCAS | 1260141-27-2;881681-01-2 |
| Inombolo yeCAT | RF-API99 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | I-C21H20FN3O6S |
| Ubunzima beMolekyuli | 461.463 |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo weCrystalline oMhlophe okanye ophantse waMhlophe |
| Ukuchongwa 1 H-NMR | Ngokungqinelana noMgangatho |
| Ukuchongwa kwe-IR | I-IR yokufunxa i-spectrum yesampulu ehambelanayo kunye nomgangatho wereferensi |
| Ukuchongwa kwe-HPLC | Ixesha lokugcinwa kwesampulu ehambelanayo kunye nomgangatho wereferensi |
| Isiqulatho samanzi | ≤0.50% |
| Intsalela kwi-Ignition | ≤0.20% |
| Iintsimbi ezinzima (njenge Pb) | ≤20ppm |
| Izinto ezinxulumeneyo | |
| Ukungcola A | ≤0.20% |
| Ukungcola B | ≤0.15% |
| Ukungcola C | ≤0.15% |
| Nakuphi na Okunye Ukungcola | ≤0.10% |
| Ukungcola ngokupheleleyo | ≤1.0% |
| Izinyibilikisi ezishiyekileyo | |
| IMethanol | ≤0.30% |
| I-Ethanol | ≤0.50% |
| I-Ethyl Acetate | ≤0.50% |
| Indlela yoVavanyo / yoHlahlelo | 98.0%~102.0% (Nge-HPLC) |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | API |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma.
I-Vonoprazan Fumurate (TAK-438) (i-CAS: 1260141-27-2; 881681-01-2), i-proton pump inhibitor (PPI), inamandla kunye nomlomo osebenzayo we-potassium-competitive acid blocker (P-CAB), ene-antisecretory. umsebenzi.I-Vonoprazan Fumarate inqanda umsebenzi we-H +, K + -ATPase kwi-porcine gastric microsomes kunye ne-IC50 ye-19 nM kwi-pH 6.5.I-Vonoprazan Fumarate (i-Takecab), ifunyenwe kwaye yaphuhliswa ngu-Takeda no-Otsuka, yamkelwa yi-PMDA yaseJapan ngoDisemba 2014. I-Vonoprazan Fumarate isetyenziselwa kakhulu unyango lwe-helicobacter pylori, i-reflux ye-gastroesophageal, i-peptic ulcer, i-duodenal ulcer, i-esophagitis, i-gas. isilonda kunye nezinye izifo ezinxulumene ne-asidi yesisu.Imveliso inesithintelo esinamandla, esihlala sihleli se-gastric acid secretion.Kwidosi yonyango, i-Vonoprazan Fumarate inefuthe elincinci kwezinye ii-enzymes kunye nefuthe elincinci kwimisebenzi ye-physiological yomzimba.Ikhuselekile kwaye iyanyamezeleka.
